URGN: Zusduri's rapid adoption and expanding pipeline signal strong growth and innovation ahead
RTGel technology underpins a growing portfolio targeting urologic cancers, with Zusduri's strong launch driven by physician demand and expanding adoption in community practices. Key milestones ahead include UGN-103 approval, new frontline studies for Zusduri, and UGN-501's entry into solid tumor tr…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.